Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Radiologia (Engl Ed) ; 65(1): 12-21, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36842781

RESUMEN

OBJECTIVE: To contribute our results to increase the scientific evidence about the use of radioembolization in the management of patients with hepatocellular carcinoma. MATERIAL AND METHODS: This retrospective review included 53 patients with hepatocellular carcinoma treated with radioembolization at our center. Patients were classified according to the BCLC algorithm in detail according to their Child-Pugh functional status. We analyzed survival using the Kaplan-Meier method. We used Cox regression analysis to determine clinically significant parameters, including the doses administered in the parameters studied. RESULTS: Patients ranged in age from 28 to 86 years (mean, 60 years). A total of 61 procedures were done. The mean activity administered was 2.8GBq (0.7-6.4GBq), with a mean dose of 229.9Gy (74-425.9Gy) administered in the tumor. Progression-free survival was 6.7 months and overall survival was 12.8 months. Differences in disease-free survival according to BCLC and Child-Pugh classification were not significant (p=0.848 and p=0.252, respectively). The clinical parameters that were significantly different with respect to overall survival were bilirubin levels (p<0.001), pretreatment transaminase levels (AST) (p=0.022), Child-Pugh subclassification (p=0.003), and dose administered in the tumor (p=0.001). Only one patient had a severe adverse reaction, developing posttreatment liver failure resulting in death. CONCLUSIONS: Radioembolization is safe and efficacious in the treatment of patients with hepatocellular carcinoma. Liver function and the doses received by the tumor are key parameters for the efficacy of treatment. The increase in the scientific evidence supports the inclusion of this technique in treatment guidelines.


Asunto(s)
Carcinoma Hepatocelular , Embolización Terapéutica , Neoplasias Hepáticas , Humanos , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Carcinoma Hepatocelular/radioterapia , Neoplasias Hepáticas/radioterapia , Supervivencia sin Enfermedad , Estudios Retrospectivos , Embolización Terapéutica/métodos
2.
Radiologia (Engl Ed) ; 2020 Nov 27.
Artículo en Inglés, Español | MEDLINE | ID: mdl-33257052

RESUMEN

OBJECTIVE: To contribute our results to increase the scientific evidence about the use of radioembolization in the management of patients with hepatocellular carcinoma. MATERIAL AND METHODS: This retrospective review included 53 patients with hepatocellular carcinoma treated with radioembolization at our center. Patients were classified according to the BCLC algorithm in detail according to their Child-Pugh functional status. We analyzed survival using the Kaplan-Meier method. We used Cox regression analysis to determine clinically significant parameters, including the doses administered in the parameters studied. RESULTS: Patients ranged in age from 28 to 86 years (mean, 60 years). A total of 61 procedures were done. The mean activity administered was 2.8 GBq (0.7-6.4 GBq), with a mean dose of 229.9Gy (74-425.9Gy) administered in the tumor. Progression-free survival was 6.7 months and overall survival was 12.8 months. Differences in disease-free survival according to BCLC and Child-Pugh classification were not significant (p=0.848 and p=0.252, respectively). The clinical parameters that were significantly different with respect to overall survival were bilirubin levels (p<0.001), pretreatment transaminase levels (AST) (p=0.022), Child-Pugh subclassification (p=0.003), and dose administered in the tumor (p=0.001). Only one patient had a severe adverse reaction, developing posttreatment liver failure resulting in death. CONCLUSIONS: Radioembolization is safe and efficacious in the treatment of patients with hepatocellular carcinoma. Liver function and the doses received by the tumor are key parameters for the efficacy of treatment. The increase in the scientific evidence supports the inclusion of this technique in treatment guidelines.

3.
Cardiovasc Intervent Radiol ; 35(6): 1488-91, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22864605

RESUMEN

PURPOSE: To report the success of groin nodal lymphography in the diagnosis and treatment of genital lymphedema. METHODS AND MATERIALS: We present one female (8 years old [patient no. 1]) and two male (69 and [patient no. 2] 31 years old [patient no. 3], respectively) patients with genital lymphedema in whom conservative treatment failed. The girl also had lymphorrhagia. Genital lymphedema was caused by radical cystectomy (patient no. 2), lymphatic hyperplasia (patient no. 1), and idiopathic lymphangitis (patient no. 3). All of them underwent ultrasound-guided bilateral groin lymph node puncture. Afterward, 4-8 ml Lipiodol Ultra-Fluide (Guerbet) were injected at a rate of 0.2 ml/s. Lipiodol progression was assessed by fluoroscopy. Computed tomography scan of the abdomen and pelvis was performed immediately after and again at 24 h after the procedure to confirm the leak. The follow-up period was 15, 13, and 9 months, respectively. Technical success was considered as bilateral pelvic and abdominal filling of lymphatic vessels. Therapeutic success was considered as improvement or disappearance of genital lymphedema and/or lymphorrhagia. RESULTS: Lipiodol leak to the scrotum was observed in patients no. 2 and 3. Lymphaticopelvic fistula and genital lymphatic hyperplasia were seen in patient no. 1. Genital lymphedema diminished within 1 week and almost disappeared in two cases (patients no. 1 and 3) or significantly improved (patient no. 2). lymphorrhagia also resolved in patient no. 1. No recurrence or worsening was detected during follow-up. CONCLUSION: Therapeutic lymphangiography by lymph node injection seems to be effective to treat genital lymphedema. Lymph node puncture lymphangiography is feasible and less cumbersome than pedal lymphangiography.


Asunto(s)
Enfermedades de los Genitales Femeninos/diagnóstico por imagen , Enfermedades de los Genitales Femeninos/terapia , Enfermedades de los Genitales Masculinos/diagnóstico por imagen , Enfermedades de los Genitales Masculinos/terapia , Linfedema/diagnóstico por imagen , Linfedema/terapia , Linfografía/métodos , Adulto , Anciano , Niño , Diagnóstico Diferencial , Aceite Etiodizado , Femenino , Fluoroscopía , Enfermedades de los Genitales Femeninos/etiología , Enfermedades de los Genitales Masculinos/etiología , Humanos , Linfedema/etiología , Masculino , Punciones , Tomografía Computarizada por Rayos X , Ultrasonografía Intervencional
4.
Transplant Proc ; 39(7): 2405-8, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17889203

RESUMEN

INTRODUCTION: Computed tomography (CT) is essential to evaluate candidates for lung transplantation (LT) We sought to correlate identification of pulmonary arterial hypertension (PAH) via CT to echocardiographic (Eco) and/or hemodynamic observations (Hd) as well as the pathological findings (Path) at posttransplant pneumonectomy. MATERIALS AND METHODS: The study included 24 consecutive months follow-up of 71 patients who were referred for LT evaluation with 54 undergoing LT. Study parameters included CT [diameter of the principal pulmonary artery (PPA) >or= 29 mm), PPA/diameter of the ascending aorta (AA) ratio > 1; diameter of the lobar artery (LA)/diameter of the lobar bronchiole (LB) ratio > 1 in three or more lobes; thickening of the anterosuperior pericardial recess (>15 mm); mosaic lung density pattern]; PAPs via Eco and/or Hd, and findings Path of PAH. Statistical analysis included chi-square and Pearson correlation coefficient. RESULTS: Thirty-five patients had PAH. Significant relationships (P < .05) were observed between PAH (Eco and/or Hd) and PPA, PPA/AA, and LA/LB. The sensitivity of the finding PPA >or= 29 mm was 65.9%, and 85.7% when combined with LA/LB > 1. In the Path study, 14/54 patients revealed alterations compatible with PAH. Significant relationships (P < .05) were observed between PAH via Path and PPA (CT) and between PAH via Path and PAH (Eco and/or Hd). CONCLUSIONS: CT is useful for the detection of PAH. Findings of PAH via CT were indicative of the need for further confirmatory studies. In contrast, the absence of findings with CT does not exclude the possible presence of PAH.


Asunto(s)
Trasplante de Corazón-Pulmón , Hipertensión Pulmonar/diagnóstico por imagen , Trasplante de Pulmón , Aorta Torácica/patología , Bronquiectasia/diagnóstico , Fibrosis Quística/diagnóstico , Ecocardiografía , Enfisema/diagnóstico , Estudios de Seguimiento , Humanos , Hipertensión Pulmonar/patología , Hipertensión Pulmonar/cirugía , Pericardio/patología , Fibrosis Pulmonar/diagnóstico , Estudios Retrospectivos , Sensibilidad y Especificidad , Tomografía Computarizada por Rayos X , Listas de Espera
5.
Transplant Proc ; 39(7): 2413-5, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17889205

RESUMEN

Mycobacterium abscessus infection following lung transplantation (LT) has been described in a few cases. It is characterized by a variable initial location and subsequent course in this special risk group of patients, particularly those with cystic fibrosis (CF). Herein we have presented the case of a patient subjected to LT due to CF, who 1 year after transplantation developed a subcutaneous nodule produced by M abscessus, with subsequent hematogenous spread as well as bronchial and bone marrow involvement. Antecedents prior to LT included Staphylococcus aureus colonization and sputum positivity for Aspergillus fumigatus and Scedosporium apioespermum. Treatment with ciprofloxacin and linezolid was started on the basis of the antibiogram findings. The latter antibiotic was replaced by clarithromycin for 6 months. Two years later, the patient remains asymptomatic with respiratory function parameters in the normal range. The infected patient described herein was our only case with sepsis and multisystemic spread. The important mortality among such cases reported in the literature makes early diagnosis and treatment essential.


Asunto(s)
Acetamidas/uso terapéutico , Antiinfecciosos/uso terapéutico , Trasplante de Pulmón/efectos adversos , Infecciones por Mycobacterium/diagnóstico , Oxazolidinonas/uso terapéutico , Complicaciones Posoperatorias/microbiología , Adolescente , Antibacterianos/uso terapéutico , Ciprofloxacina/uso terapéutico , Fibrosis Quística/cirugía , Humanos , Linezolid , Masculino , Mycobacterium/clasificación , Mycobacterium/aislamiento & purificación , Esputo/microbiología
7.
Transplant Proc ; 37(9): 4059-63, 2005 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-16386626

RESUMEN

Lymphoproliferative syndromes are the most common tumors in transplant recipients. More than 90% of posttransplantation lymphoproliferative syndromes (PTLS) are considered to be associated with Epstein-Barr virus, and 86% are of the B-cell line. Histopathology ranges from polymorphic-reactive to monomorphic forms. Clonality should be studied using molecular biology techniques. Clinically, a differentiation is usually made between early PTLS (occurring within 1 year after transplantation) and late PTLS, which occur as localized or disseminated nodal lymphomas. In localized forms, immunosuppression should be discontinued or decreased, and the involved area should be subsequently resected or irradiated. In disseminated cases, immunosuppression should be decreased and administration of acyclovir/ganciclovir should be considered. If this is not effective, treatment should be started with anti-CD20 monoclonal antibodies (rituximab). If no response occurs, use of chemotherapy, possibly with interferon, should be considered. Our aim was to report the incidence, clinical signs, and treatment in a series of patients undergoing lung transplantation (LTx).


Asunto(s)
Trasplante de Corazón-Pulmón/efectos adversos , Inmunosupresores/efectos adversos , Trasplante de Pulmón/efectos adversos , Trastornos Linfoproliferativos/diagnóstico , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Linfoma de Burkitt/diagnóstico , Linfoma de Burkitt/tratamiento farmacológico , Femenino , Trasplante de Corazón-Pulmón/inmunología , Enfermedad de Hodgkin/diagnóstico , Enfermedad de Hodgkin/tratamiento farmacológico , Humanos , Pulmón/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Tomografía Computarizada por Rayos X
8.
Rev Esp Anestesiol Reanim ; 50(10): 521-5, 2003 Dec.
Artículo en Español | MEDLINE | ID: mdl-14737778

RESUMEN

A 69-year-old woman, with an aortic replacement valve for rheumatic aortic insufficiency suffered a sudden cardiac tamponade caused by a ruptured pseudoaneurysm of the ascending aorta which had its origin in the suture of the aorta performed 10 years earlier. The cardiac tamponade presented as syncope, absent central pulse, and respiratory failure. Hemodynamic variables recovered with early detection and start of cardiopulmonary resuscitation maneuvers. After fluids were replaced and following catecholamine treatment, a transesophageal echocardiogram revealed a pseudoaneurysm and continuous flow between the aorta and the right ventricle. The aneurysm and an unusual right ventricular fistula were repaired surgically through an emergency exploratory sternotomy. Cardiovascular recovery was satisfactory although hospital discharge was delayed because of pulmonary complications leading to severe hypoxia, pleural effusion, and pneumonia, with tracheal aspirate and bronchoalveolar lavage cultures positive for Pseudomonas aeruginosa, Acinetobacter spp, and Aspergillus flavus. We stress that immediate start of cardiopulmonary resuscitation prevented multiorgan failure and allowed for satisfactory recovery from surgery in spite of the presence of risk factors for mortality.


Asunto(s)
Aneurisma Falso/complicaciones , Enfermedades de la Aorta/complicaciones , Taponamiento Cardíaco/etiología , Cardiomiopatías/complicaciones , Fístula/complicaciones , Fístula Vascular/complicaciones , Anciano , Aorta Torácica , Femenino , Ventrículos Cardíacos , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA